

# HHV-8 gp64 (11D1): sc-65444

## BACKGROUND

HHV-8, also designated Kaposi's sarcoma-associated herpesvirus (KSHV), is associated with multicentric Castleman's disease and primary effusion lymphoma, a rare type of non-Hodgkin lymphoma affecting the body cavities. This virus commonly infects AIDS patients or people with weakened immune systems and gives rise to Kaposi's sarcoma which is a form of cancer that arises from lymphatic endothelium. HHV-8 gp64 is a glycoprotein that is located on the surface of the HHV-8 virion envelope. Evidence suggests that this protein may play a significant role in cell to cell transmission of the virus.

## REFERENCES

- Chandran, B., Bloomer, C., Chan, S.R., Zhu, L., Goldstein, E. and Horvat, R. 1998. Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. *Virology* 249: 140-149.
- Zhu, L., Wang, R., Sweat, A., Goldstein, E., Horvat, R. and Chandran, B. 1999. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. *Virology* 256: 381-392.
- Zhu, L., Puri, V. and Chandran, B. 1999. Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies. *Virology* 262: 237-249.
- Wu, L., Renne, R., Ganem, D. and Forghani, B. 2000. Human herpesvirus 8 glycoprotein K8.1: expression, post-translational modification and localization analyzed by monoclonal antibody. *J. Clin. Virol.* 17: 127-136.
- Tedeschi, R., Kvarnung, M., Knekt, P., Schulz, T.F., Szekely, L., De Paoli, P.D., Aromaa, A., Teppo, L. and Dillner, J. 2001. A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. *Br. J. Cancer* 84: 122-125.
- Wang, F.Z., Akula, S.M., Pramod, N.P., Zeng, L. and Chandran, B. 2001. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. *J. Virol.* 75: 7517-7527.
- Luna, R.E., Zhou, F., Baghian, A., Chouljenko, V., Forghani, B., Gao, S.J., Kousoulas, K.G. 2004. Kaposi's sarcoma-associated herpesvirus glycoprotein K8.1 is dispensable for virus entry. *J. Virol.* 78: 6389-6398.
- He, F., Wang, X., He, B., Feng, Z., Lu, X., Zhang, Y., Zhao, S., Lin, R., Hui, Y., Bao, Y., Zhang, Z. and Wen, H. 2007. Human herpesvirus 8: seroprevalence and correlates in tumor patients from Xinjiang, China. *J. Med. Virol.* 79: 161-166.

## SOURCE

HHV-8 gp64 (11D1) is a mouse monoclonal antibody raised against HHV-8 gp64.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PRODUCT

Each vial contains 200 µg IgG<sub>2b</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

HHV-8 gp64 (11D1) is available conjugated to agarose (sc-65444 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-65444 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-65444 PE), fluorescein (sc-65444 FITC), Alexa Fluor® 488 (sc-65444 AF488), Alexa Fluor® 546 (sc-65444 AF546), Alexa Fluor® 594 (sc-65444 AF594) or Alexa Fluor® 647 (sc-65444 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-65444 AF680) or Alexa Fluor® 790 (sc-65444 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

## APPLICATIONS

HHV-8 gp64 (11D1) is recommended for detection of HHV-8 gp64 of viral origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500); non cross-reactive with Epstein-Bar Virus.

Molecular Weight of HHV-8 gp64: 55 kDa.

## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

## SELECT PRODUCT CITATIONS

- Granato, M., Gilardini Montani, M.S., Angiolillo, C., D'Orazi, G., Faggioni, A. and Cirone, M. 2018. Cytotoxic drugs activate KSHV lytic cycle in latently infected PEL cells by inducing a moderate ROS increase controlled by HSF1, NRF2 and p62/SQSTM1. *Viruses* 11 pii: E8.
- Santarelli, R., Carillo, V., Romeo, M.A., Gaeta, A., Nazzari, C., Gonnella, R., Granato, M., D'Orazi, G., Faggioni, A. and Cirone, M. 2019. STAT3 phosphorylation affects p53/p21 axis and KSHV lytic cycle activation. *Virology* 528: 137-143.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.